Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2021-09-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于员工持股计划锁定期届满的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Tian Kang Biological Co., Ltd. regarding the expiration of the lock-up period of its 2020 employee stock ownership plan. It details the background, stock holding situation, lock-up period, post-lock-up arrangements, continuation, changes, and termination of the employee stock ownership plan. The document does not contain financial statements or detailed financial data but is an informative notice about the status and regulatory compliance of the employee stock ownership plan. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or a proxy solicitation. Given the nature of the content, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about the employee stock ownership plan status and compliance, which does not fit other more specific categories.
2021-09-13 Chinese
关于2021年8月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for August 2021 from Tian Kang Biological Co., Ltd., detailing sales volume and revenue of live pigs, with month-over-month and year-over-year comparisons. It includes a risk warning and clarifies that the data is unaudited and only represents a segment of the business. The document is short (889 characters) and serves as a periodic sales update rather than a comprehensive financial report. It does not contain full financial statements or detailed analysis typical of interim or annual reports. It is not an earnings release since it focuses on sales volume and revenue for a specific product segment and is labeled as a sales brief. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement or compliance document that does not fit other specific categories.
2021-09-08 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective from January 1, 2021. It details the reasons for the change, the new accounting policies, and the opinions of the board, independent directors, and supervisory board. The document is relatively short (2184 characters) and does not contain actual financial statements or detailed financial data. It is an official announcement about a change in accounting policy rather than a full financial report or audit report. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-08-26 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 7th Board of Directors of Tian Kang Biological Co., Ltd. It includes voting results on various proposals such as approval of the 2021 semi-annual report, a special report on the use of raised funds, increase in futures hedging business limits, changes in accounting policies, and related independent directors' opinions. The document does not contain the full semi-annual report or detailed financial statements but references where these reports can be found (e.g., Securities Times newspaper and cninfo.com.cn). The document is relatively short (2356 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or resolutions.
2021-08-26 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled '天康生物股份有限公司 2021 年半年度报告摘要' which translates to 'Tiankang Biological Co., Ltd. 2021 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period of 2021, including revenue, net profit, earnings per share, asset and liability figures, shareholder information, and bond details. The document also references the full semi-annual report and advises investors to read the full report for comprehensive information. The presence of substantive financial data and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (4781 characters) is sufficient to contain actual financial data, not just an announcement or summary. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2021
2021-08-26 Chinese
关于增加套期保值业务额度的可行性分析报告
Management Reports Classification · 95% confidence The document is a detailed analysis report regarding the feasibility of increasing the company's commodity futures hedging business quota. It discusses the purpose, necessity, risk analysis, and risk control measures related to the futures hedging business. The document is issued by the company's board and dated August 27, 2021. It is not a financial report like an annual or interim report, nor is it an announcement of voting results or a regulatory filing. It is a management-level report focused on a specific business strategy and risk management related to hedging activities. Therefore, it fits best under the category of Management Reports (MDA), which covers management's detailed explanation of business trends and outlooks related to financial and operational matters.
2021-08-26 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.